Assertio Holdings, Inc. To Report Third Quarter 2024 Financial Results On November 11, 2024
Date
10/30/2024 8:16:21 AM
(MENAFN- GlobeNewsWire - Nasdaq) LAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the“Company”) (Nasdaq: ASRT), a Pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release third quarter 2024 financial results on Monday, November 11, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at . Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-646-307-1963. The call ID is 3278948.
A webcast replay of the call will be available approximately two hours after the call on Assertio's investor website.
About Assertio
Assertio is a commercial pharmaceutical company offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit .
Investor Contact
Matt Kreps
Darrow Associates Investor Relations
+1-214-597-8200
...
MENAFN30102024004107003653ID1108833405
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.